Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 93 results found since Jan 2013.
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report
Medicina (Kaunas). 2021 Dec 13;57(12):1358. doi: 10.3390/medicina57121358.ABSTRACTAnti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented with myalgia, Gottron's papules with ulceration, and dyspnea on exertion which became aggravated within weeks. Laboratory examination and electromyography confirmed myopathy changes, and a survey of myositis-specific antibodies was strongly positi...
Source: Medicina (Kaunas) - December 24, 2021 Category: Universities & Medical Training Authors: Tsai-Hung Yen Chih-Wei Tseng Kao-Lun Wang Pin-Kuei Fu Source Type: research
Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature
ConclusionDespite a lack of rigorous clinical trials, considerable experience demonstrated that anti-B-cell therapy might be effective for patients with IMNM associated with anti-SRP antibodies. Belimumab in association with steroids might be an encouraging option for refractory/relapsing cases.
Source: Frontiers in Immunology - December 2, 2021 Category: Allergy & Immunology Source Type: research
Inflammatory myopathies: Shedding light on promising agents and combination therapies in clinical trials
Expert Opin Investig Drugs. 2021 Nov 14. doi: 10.1080/13543784.2021.2003776. Online ahead of print.ABSTRACTINTRODUCTION: Due to new insights into the pathogenesis of inflammatory myopathies -in short myositis- and the urgent need for new treatment options in patients who are refractory to standard therapy, multiple novel drugs have been developed and studied in clinical trials. In light of this exciting development, a critical evaluation of the present data is necessary in order to identify the best pathway to future treatment of inflammatory myopathies.AREAS COVERED: This review focuses on the current evidence from clinic...
Source: Expert Opinion on Investigational Drugs - November 15, 2021 Category: Drugs & Pharmacology Authors: Rachel Zeng Stefanie Glaubitz Jens Schmidt Source Type: research
Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin
We describe a 68-year-old man who presented with progressive weakness in proximal muscles of all four limbs and was found to have autoantibody-negative necrotizing autoimmune myopathy (NAM). His myopathy was refractory to corticosteroids and methotrexate, but subsequently demonstrated successful response to intravenous immunoglobulin (IVIG). The patient also received rituximab, but the timing of his recovery favored IVIG as the more important factor in terms of efficacy. Treatment guidelines for seronegative necrotizing myopathies are lacking. This case suggests a potential efficacious treatment option for the seronegative...
Source: Baylor University Medical Center Proceedings - July 5, 2021 Category: Universities & Medical Training Authors: Rebecca Liu Andrew Z Fenves Samantha N Champion Jonathan Dau Source Type: research
